drugset / Trial / NCT01710566
Misoprostol and Oxytocin in Uniject® for Postpartum Hemorrhage Prevention in Communities
Phase 3
Withdrawn
Gynuity Health Projects
Aga Khan Health Services · collabDepartment of Health and Family Welfare, Government of Gujarat · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
This community-based cluster Randomised Control Trial will assess the feasibility, cost, risks and benefits of use of oral Misoprostol and parenteral Oxytocin in Uniject® as prophylaxis for postpartum hemorrhage (PPH) in community settings. The study will be conducted in Jamnagar district in Gujarat state in India. The hypothesis is that a program to deliver oral misoprostol and one to deliver oxytocin via Uniject® will both be effective in preventing PPH when introduced in community-based settings.
Timeline
- Start
- 2013-07
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Misoprostol | Other / unclassified | 600 ug | Oral |
| Subject | Oxytocin | Peptide | 10 iu | Intramuscular |
Indications
No indication recorded.